Novartis chief executive says large pharma deals usually don't pay off. But the company remains interested in bolt-on ...
Reports Q4 revenue $13.2B vs. $11.4B last year. Vas Narasimhan, CEO of Novartis (NVS), said: “In our first full year as a pure-play innovative ...
Novartis was among the most prolific pharma dealmakers in 2024, a trend that it expects to continue with more bolt-on deals this year to set up for sustainable long-term growth.
The American CEO of Swiss drugmaker Novartis on Friday warned that the United States' exit from the World Health Organization ...
Swiss drug-major Novartis AG reported Friday weak net earnings in its fourth quarter on the absence of prior year's significant gain ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback